Buprenorphine Induction Protocol

Office-Based Treatment for Opioid Use Disorder — PMHNP Clinical Guide

ICD-10:F11.20 · F11.23
1

Background & Mechanism

  • Buprenorphine: Partial μ-opioid receptor agonist + κ antagonist
  • High receptor affinity → displaces full agonists (this causes precipitated withdrawal if used too early)
  • Ceiling effect on respiratory depression (safety advantage)
  • Target dose: 16-24 mg/day (most patients)
  • Formulations: Suboxone (buprenorphine/naloxone), Subutex (buprenorphine mono), Sublocade (SQ monthly)
⚠ The Current Crisis

Illicit fentanyl has longer tissue half-life and higher receptor affinity than heroin, requiring modified induction approaches to prevent precipitated withdrawal.

2

Pre-Induction Assessment

📋 Pre-Induction Checklist
Confirm OUD diagnosis (DSM-5 criteria, 2+ symptoms)
Determine current opioid type (heroin vs fentanyl vs prescription opioids vs combination)
Assess time since last opioid use
Obtain COWS score (require ≥8 for standard induction; fentanyl patients may need ≥12)
Review LFTs (buprenorphine hepatically metabolized)
Screen for benzodiazepine/alcohol use (concurrent CNS depressants — safety risk)
Review medications for interactions (CYP3A4)
Assess pregnancy status (use buprenorphine mono if possible)
Co-prescribe naloxone (Narcan) kit
Assess motivation and social support
Discuss home induction vs office-based
🎯 Critical Decision Point

Current opioid type determines induction method:

• Short-acting opioids → Standard induction (COWS ≥8)

• Fentanyl/long-acting → Low-dose/microdose preferred

3

COWS Scoring Tool

Clinical Opiate Withdrawal Scale — assess severity of opioid withdrawal

Sign/Symptom Scoring Points
Resting Pulse Rate <80 = 0 | 81-100 = 1 | 101-120 = 2 | >120 = 4 0-4
Diaphoresis Absent = 0 | Slight = 1 | Moderate = 2 | Heavy = 3 | Soaked = 4 0-4
Restlessness None = 0 | Slight = 1 | Moderate = 2 | Severe = 3 | Constant motion = 4 0-4
Pupil Size Normal = 0 | Possibly enlarged = 1 | Dilated = 2 | Very dilated = 3 | Extremely dilated = 5 0-5
Bone/Joint Aches None = 0 | Mild = 1 | Moderate = 2 | Severe = 3 | Very severe = 4 0-4
Runny Nose / Tearing None = 0 | Mild = 1 | Moderate = 2 | Severe = 3 | Very severe = 4 0-4
GI Upset None = 0 | Nausea = 1 | Nausea/cramps = 2 | Vomiting/diarrhea = 3 | Severe = 4 | Constant = 5 0-5
Tremor None = 0 | Slight = 1 | Moderate = 2 | Severe = 3 | Very severe = 4 0-4
Yawning None = 0 | Few (1-2) = 1 | Several (3-4) = 2 | Frequent = 3 | Constant = 4 0-4
Anxiety / Irritability None = 0 | Mild = 1 | Moderate = 2 | Severe = 3 | Very severe = 4 0-4
Gooseflesh Skin Absent = 0 | Piloerection = 1 | Prominent = 2 | Constant = 3 0-3

Score Interpretation

Score Range Severity Clinical Significance
5-12 Mild withdrawal Too early for induction
13-24 Moderate withdrawal Optimal for standard induction
25-36 Moderately severe Safe to proceed; comfort measures needed
>36 Severe High distress; comfort meds essential
📊 Induction Thresholds

For standard induction: Proceed when COWS ≥8-12

For fentanyl patients: May need COWS ≥12 or use microdose protocol

4

Induction Methods Comparison

Method Indication Withdrawal Required? Setting Key Consideration
Standard Induction Short-acting opioid use Yes (COWS ≥8) Office or home Classic approach; risk of PW with fentanyl
Low-Dose Induction Fentanyl, long-acting opioids No Office Start 0.5-2mg, overlap with full agonist
Microdose (Bernese) Fentanyl, high-risk patients No (patient continues using) Office/home Best for fentanyl; graded over 5-7 days
Home Induction Motivated patients, short-acting Yes (must achieve COWS ≥8 at home) Home Telehealth support; clear written instructions required
Telehealth Induction All types (COVID-era protocols) Per method Remote DEA exemption rules apply; video required
5

Standard Induction Protocol

For short-acting opioids — day-by-day protocol

Day 0 — Pre-Induction
  • Last use of short-acting opioids ≥12 hours ago
  • Achieve COWS ≥8-12 in office
  • If heroin: wait until objective signs present
Day 1 (Office-Based)
  • Starting dose: 2-4 mg SL buprenorphine/naloxone
  • Wait 30-60 minutes, reassess COWS and comfort
  • If still symptomatic: additional 2-4 mg SL
  • Maximum Day 1 dose: 8-12 mg
  • Do NOT discharge until patient comfortable (COWS <8)
Day 2
  • Yesterday's total dose given as single daily dose or twice daily
  • Continue to titrate upward by 2-4 mg daily until comfort achieved
Day 3-7
  • Titrate to comfort dose (typically 16-24 mg/day)
  • Weekly visits during first month
  • Urine drug screen at each visit

Timing Requirements by Opioid Type

Opioid Type Minimum Wait Time Notes
Short-acting opioids ≥12 hours Oxycodone, hydrocodone, etc.
Heroin ≥12-18 hours Wait for objective signs
Methadone ≥24-72 hours Highest PW risk
Fentanyl ≥24 hours Highly variable — prefer microdose
6

Low-Dose / Microdose (Bernese) Protocol

Fentanyl-Adapted Approach

🧬 The Patient Does NOT Need to Stop Opioid Use First

Buprenorphine is introduced at sub-threshold doses while continuing the full agonist, then the full agonist is tapered.

💡 Why This Works

At very low doses, buprenorphine occupies receptors without displacing the full agonist completely, avoiding precipitated withdrawal.

Sample Bernese Schedule (7-Day)

Day Buprenorphine Dose Full Agonist
1 0.5 mg SL once Continue as usual
2 0.5 mg SL twice Continue
3 1 mg SL twice Begin taper if willing
4 2 mg SL twice Reduce by 25-50%
5 4 mg SL twice Reduce further
6 8 mg SL twice Discontinue or minimal
7 12-16 mg SL daily Discontinue
📝 Clinical Note

Variations exist. Work with patient to adapt schedule. Some patients prefer longer transitions.

7

Home Induction Protocol

✅ Patient Selection Criteria
Motivated and reliable patient
Using short-acting opioids only (no fentanyl)
Ability to accurately assess own COWS score
Support person available if possible
Reliable phone/contact for telehealth support

Required Materials

  • Prescription for 8-16 mg buprenorphine/naloxone (2-4 mg tablets preferred)
  • Written instructions (provide copy to patient)
  • COWS scoring guide
  • 24/7 contact number for emergencies
  • Naloxone kit prescribed

Instructions for Patient

  1. Wait until in moderate withdrawal (COWS ≥8)
  2. Take first 2-4 mg SL tablet
  3. Wait 1 hour; if still uncomfortable, take another 2-4 mg
  4. Maximum first day: 8-12 mg
  5. Contact clinic next business day to report progress
  6. Return to office within 3-7 days for follow-up
8

Telehealth Induction

📡 COVID-Era Protocols

DEA exemptions allow telehealth initiation of buprenorphine. Requirements vary by state.

Requirements

  • Video visit required — audio-only insufficient
  • Real-time, synchronous interaction
  • Provider must be DATA 2000 waivered (X-waiver)
  • Documentation of OUD diagnosis
  • Appropriate screening and safety planning

Process

  1. Initial telehealth assessment (full history, COWS via video)
  2. E-prescribe to pharmacy (if allowed in your state)
  3. Written instructions sent electronically
  4. Follow-up within 3 days (telehealth or in-person)
  5. Transition to in-person care when feasible
⚠ Important

State regulations vary significantly. Some states require at least one in-person visit. Verify your state's specific requirements.

9

Maintenance Phase

Target Dose

16-24 mg/day for most patients (higher doses associated with better outcomes)

Monitoring Schedule

Component Frequency Notes
Office visits Monthly (after first 3 months if stable) More frequent initially
Urine drug screen Each visit Include buprenorphine level
PHQ-9 Quarterly Depression comorbid in 50%+ of OUD
Other SUD assessment Ongoing Alcohol, benzodiazepines, stimulants
⏱️ Duration of Treatment

Indefinite for most patients.

Evidence: Early discontinuation dramatically increases overdose risk. 2-year treatment retention associated with 50% reduction in overdose death.

Formulation Considerations

Formulation Dosing Advantages
Suboxone
buprenorphine/naloxone 4:1		 Daily SL Standard; naloxone deters IV misuse
Sublocade
Monthly SQ injection		 300 mg × 2 mo, then 100 mg/mo Eliminates daily adherence problem
Brixelle
Weekly SQ		 Weekly injection Alternative extended-release option
10

Managing Precipitated Withdrawal

⚠ What is Precipitated Withdrawal?

Buprenorphine's high affinity displaces full agonists abruptly → sudden, severe withdrawal syndrome

Signs of Precipitated Withdrawal

Onset within 30-60 minutes of first dose:

  • Sudden severe anxiety/agitation
  • Intense nausea/vomiting
  • Severe muscle cramping
  • Diaphoresis, piloerection
  • COWS score suddenly ↑↑

Management Protocol

  1. Do NOT give more buprenorphine initially (may worsen)
  2. Comfort measures: anti-emetics, clonidine 0.1 mg PO (reduces autonomic symptoms), NSAIDs
  3. Monitor vitals every 30 minutes
  4. If severe: Small additional buprenorphine (2-4 mg) CAN help once initial PW begins to plateau
  5. Clonidine 0.1-0.3 mg PO q8h PRN
  6. Reassure patient — this is time-limited (usually resolves in 4-12 hours)
🛡️ Prevention

COWS ≥8 before ANY dose; microdose for fentanyl patients

11

Special Populations

🤰 Pregnancy

  • Buprenorphine (mono) preferred over methadone in many settings
  • Suboxone (with naloxone) generally avoided in pregnancy
  • NAS is expected — NOT a reason to withhold treatment
  • Dose may need increase in 3rd trimester

💊 Chronic Pain

  • Higher buprenorphine doses may be needed
  • Provides partial analgesia (especially at divided doses)
  • For acute pain: short-acting opioids may have reduced effect
  • NSAIDs, regional anesthesia preferred for acute pain

🩺 Hepatic Impairment

  • Monitor LFTs; generally safe with mild-moderate hepatic disease
  • Severe hepatic impairment: use with caution, reduce dose
  • Buprenorphine hepatically metabolized via CYP3A4
12

Clinical Pearls

1

"Don't start too early, don't wait too long" — COWS ≥8 is the sweet spot for standard induction

2

"Fentanyl changes everything" — the standard 12-hour wait is insufficient; use microdose

3

"Higher doses = better outcomes" — 16-24 mg associated with significantly better retention than 8 mg

4

"Prescribe naloxone every time" — co-prescription is standard of care regardless of formulation

5

"Suboxone doesn't get patients high — it gets them well" — patient education is critical for adherence

6

"Early discontinuation kills" — most overdose deaths occur in first 30 days after stopping

7

"Telehealth can initiate buprenorphine" — DEA exemptions exist; know your state regulations

13

References

  • SAMHSA TIP 63: Medications for Opioid Use Disorder (2021)
  • ASAM National Practice Guideline for MOUD (2020)
  • Herring AA et al. Low-dose buprenorphine induction (Bernese method). Ann Emerg Med 2019
  • Lee JD et al. XR-NTX vs Buprenorphine (X:BOT Trial). Lancet 2018
  • Mattick RP et al. Buprenorphine maintenance vs placebo. Cochrane 2014
  • Wakeman SE et al. Comparative effectiveness of MOUD. JAMA Intern Med 2020